United Therapeutics Corporation (UTHR)
NASDAQ
Healthcare
Biotechnology
$552.48
▼ -0.34%
Market Cap
$23.45B
Sector
Healthcare
Industry
Biotechnology
Beta
0.58
52-Wk Range
272.12-609.35
CEO
Martine A. Rothblatt
Country
US
Currency
USD
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in …
Open full interactive analysis & DCF →